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ABSTRACT 
 
Background 
Most large acute stroke trials have been neutral.  Functional outcome is usually 
analysed using a yes or no answer, e.g. death or dependency vs. independence.  We 
assessed which statistical approaches are most efficient in analysing outcomes from 
stroke trials. 
 
Methods 
Individual patient data from acute, rehabilitation and stroke unit trials studying the 
effects of interventions which alter functional outcome were assessed. Outcomes 
included modified Rankin Scale, Barthel Index, and ‘3 questions’. Data were analysed 
using a variety of approaches which compare two treatment groups. The results for 
each statistical test for each trial were then compared.  
 
Results 
Data from 55 datasets were obtained (47 trials, 54,173 patients). The test results 
differed substantially so that approaches which use the ordered nature of functional 
outcome data (ordinal logistic regression, t-test, robust ranks test, bootstrapping the 
difference in mean rank) were more efficient statistically than those which collapse 
the data into 2 groups (chi square) (ANOVA p<0.001). The findings were consistent 
across different types and sizes of trial and for the different measures of functional 
outcome. 
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Conclusions 
When analysing functional outcome from stroke trials, statistical tests which use the 
original ordered data are more efficient and more likely to yield reliable results. 
Suitable approaches included ordinal logistic regression, t-test, and robust ranks test. 
 
3 
BACKGROUND 
 
The management of patients with acute or recent stroke has benefited significantly 
from the results of randomised controlled trials and meta-analyses of these. For 
example, functional outcome is improved with alteplase, aspirin, management in a 
Stroke Unit, and community occupational therapy.1-7 In contrast, some studies were 
overtly negative finding that treatment worsened outcome, e.g. DCLHb, enlimomab, 
selfotel, or tirilazad.8-11  However, the majority of acute stroke trials were neutral in 
spite of positive preclinical findings. The failure of these latter studies can be 
attributed to multiple causes, including the relevance of laboratory findings to clinical 
stroke,12 inadequate sample size,13 choice of primary outcome, and its statistical 
analysis. 
 
Measures of functional outcome such as the modified Rankin Scale (mRS)14, Barthel 
Index (BI)15 and ‘3-questions’’16 are ordinal in nature, that is, they consist of 3 or 
more categories which have a natural ordering, e.g. the mRS has 7 categories ranging 
from no symptoms to dead. It might then be expected that statistical analysis would 
preserve and utilise the data in this ordinal form. However, most published trials have 
used a ‘yes/no’ (dichotomised) analysis of functional outcome, e.g. combining 
categories within the mRS into two groups, such as ‘dead or dependent’ (e.g. mRS 3-
6) and ‘independent’ (mRS 0-2), and then comparing these between the treatment 
groups. Unfortunately, there is little agreement where mRS data should be divided: 
i.e. 0,1 vs. 2-6,1 0-2 vs. 3-6,17 or 0-3 vs. 4-6,18 and whether this matters.19 Further, 
collapsing data in this way generally lowers statistical power and therefore reduces 
the chance of finding a significant treatment effect since information from many 
subjects are ignored. For example, patients responding to treatment and achieving a 
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mRS of 3 rather than 4 or 0 rather than 1 are not detected in a analysis comparing 
mRS 0-2 with 3-6. 
 
Inadequacies in the statistical analysis of trials in acute stroke are apparent in two 
examples. First, the ECASS II trial of alteplase showed no treatment effect for its 
primary outcome (when comparing mRS 0,1 with mRS 2-6) but was positive when re-
analysed using the data collapsed in a different place (mRS 0-2 vs. 3-6) 20  or when 
analysed using a ‘bootstrapping’ technique (figure 1).21 Second, five trials of tirilazad 
individually showed no treatment effect when analysed using dichotomous outcomes 
22-24 although a meta-analysis found that the intervention was associated with a worse 
outcome;25 post hoc analysis then suggested that one of these trials was negative24 
(not neutral) when analysed using a method which preserved the original ordered 
data (P Bath, unpublished data). 
 
We aimed to identify which statistical methods might optimise the analysis of data 
from functional outcome scales in stroke trials. 
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METHODS 
 
Identification of trials 
We sought individual patient data from randomised controlled trials assessing 
functional outcome after stroke for interventions which were either positive or 
negative according to the trial publication, or were included in a meta analysis 
showing benefit or harm; neutral trials in a neutral meta-analysis were excluded. 
Published studies (full paper or abstract) fulfilling these criteria were identified from 
electronic searches of the Cochrane Library (to end of 2005). In each case, we invited 
the chief investigator to join the collaboration and share their data. In some cases 
where individual data could not be obtained it was possible to extract it from the 
original publication. 
 
Trial data 
Demographic (age, gender), trial (setting, intervention, length of follow up, result), 
patient severity, and functional outcome (BI, mRS, ‘3 question’ scale [3Q, a derivative 
of mRS], or another measure) data were collected for each trial. In factorial trials or 
those having more than two treatment groups, data were analysed for each 
comparison of active therapy versus control. Where outcome data were scored at 
several time points (e.g. 1, 3 and 6 months) the time point used for the primary 
outcome was included. 
 
Statistical tests 
We compared different statistical tests for assessing treatment effect. Some of these 
required the data to be collapsed into groups (such as the chi square test) while 
others used the original ordinal data (such as Wilcoxon test and t-test). Statistical 
tests which dichotomised (‘yes/no’) data were assessed multiple times collapsing the 
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data in different places, e.g. mRS 0,1 vs. 2-6, 0-2 vs. 3-6 and 0-5 vs. 6. A description 
of the statistical tests used is given in http://www.nottingham.ac.uk/stroke-
medicine/oast/oastappendix1.doc. 
 
Comparison of statistical tests 
Each data set was analysed using each statistical test. These results were then 
ordered within each trial and given a rank, with the lowest rank given to the test 
which produced the most significant result, i.e. the largest z score, within that trial. A 
two-way analysis of variance test was then used to see on average which statistical 
test had produced the lowest ranks. We were then able to order the statistical tests in 
terms of their efficiency in identifying treatment effects. We also assessed how many 
statistically significant (at 5%) results each test found. 
 
To assess the validity and reliability of the results, a number of supplementary 
analyses were carried out. First, the comparison of statistical tests was repeated 
within sub-groups of trials sharing similar characteristics; second, the statistical 
assumptions of the tests were assessed; and last, the sensitivity of the tests was 
explored to make sure treatment effects were only detected when they truly existed 
(the type one error rate). Technical details of these supplementary analyses can be 
found in http://www.nottingham.ac.uk/stroke-medicine/oast/oastappendix2.doc. 
 
Analyses were carried out in SAS (version 8.2) and Stata (version 7) and significance 
was taken at p<0.05. 
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RESULTS 
 
Trials characteristics 
A total of 55 comparisons of active versus control treatment (54,173 patients) were 
included, these comprising individual patient data from 38 trials and summary data 
extracted from the publications of a further 9 studies; six trials had two active 
treatment groups, and one had three active groups so a further 8 comparisons were 
available (figure 2). The data related to 34 acute stroke trials, 7 trials of rehabilitation 
(1,164 patients) and 6 trials of stroke units (1,399 patients). BI was used to measure 
functional outcome in 22 trials, 18 used the mRS, 3 used the 3Q scale, 1 used the 
Rivermead scale, 2 related trials used the Nottingham ADL scale, and 1 trial used its 
own ordinal measure.26 Included trials studied the following interventions: abciximab 
(AbESTT); alteplase (ATLANTIS A & B, ECASS II, NINDS); aspirin (CAST, IST); 
atenolol (BEST); citicoline; DCLHb; ebselen; edaravone; enlimomab (EAST); factor 
VIIa; feeding (FOOD 3); nadroparin (FISS, FISS-TRIS); nimodipine (INWEST); 
occupational therapy (Corr, Gilbertson, Logan, TOTAL, Walker); physiotherapy 
(Young); pro-urokinase (PROACT II); selfotel (ASSIST); streptokinase (ASK, MAST-E, 
MAST-I); stroke unit (Dover, Helsinki, Kuopio, Nottingham, Orpington, Newcastle); 
and tirilazad (RANTTAS I & II, STIPAS, TESS I & II). Data relating to 16 trials or 
interventions which fulfilled the inclusion criteria were not made available. 
 
The method of analysing functional outcome used in the original trial publication 
varied considerably, see http://www.nottingham.ac.uk/stroke-
medicine/oast/oastappendix3.doc. 23 (48.9%) trials assessed the treatment effect 
using a method which required the data to be collapsed into groups, e.g. chi-square 
test; 17 (36.2%) used a test based on comparing medians and 4 (8.5%) used a test 
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which compared means; the remaining trials were unpublished so the method of 
analysis is not known. 
 
Comparison of statistical tests 
The statistical tests assessed differed significantly in the results they gave for each 
trial (2 way ANOVA p<0.0001). The ordering of the tests showed that those which 
analyse the original ordinal data generally perform better than those which collapse 
the data into 2 or more groups. The most efficient tests included ordinal logistic 
regression, t-test, robust rank test and bootstrapping the difference in mean rank 
(table 1). The sub group analysis showed the same ordering of tests irrespective of 
type of intervention (acute, rehabilitation, stroke unit), trial size, time between 
randomisation and onset, patient age, baseline severity, outcome measure, length of 
follow up, and trial result (http://www.nottingham.ac.uk/stroke-
medicine/oast/oastappendix4.doc). 
 
When assessed by how many trials were statistically significant, those tests which did 
not collapse the data into groups again out-performed the other approaches; for 
example, ordinal logistic regression (using raw data) gave a statistically significant 
result in 25.9% of trials whereas the 2x2 chi-square test comparing death or poor 
outcome to an excellent outcome only gave a significant result in 9.3% of the trials 
(figure 3). 
 
Test assumptions and sensitivity 
The statistical assumptions of the t-test were not met for the majority of trials and the 
assumptions of the ordinal logistic regression analysis failed for 8 out of the 55 data 
sets; in contrast, the assumptions for the other tests were maintained. The sensitivity 
analysis showed that the top performing statistical tests were not overly sensitive and 
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statistically significant treatment effects were only found where they truly existed; see 
http://www.nottingham.ac.uk/stroke-medicine/oast/oastappendix5.doc for detailed 
results. 
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DISCUSSION 
 
These results show that statistical approaches which analyse the original ordinal data 
for functional outcome are more efficient than those which work on pre-processed 
data which has been collapsed into 2 or more groups. Interestingly, this point was 
originally demonstrated mathematically by Shannon in 1948 27. In particular, ordinal 
logistic regression, t-test, robust ranks test, and bootstrapping (the difference in 
mean rank) performed well and appear to be useful irrespective of the type of stroke 
trial, patient or intervention.  Although individual tests based on dichotomised data 
using Chi-square analysis (e.g. ‘dead/dependent’ versus ‘independent’) were effective 
for some data sets, they performed poorly in many and therefore cannot be 
recommended as general solutions for analysing stroke trials. From an historical 
perspective, it is quite possible that trials which collapsed mRS or BI in two groups 
may have used a sub-optimal analysis, and this may have contributed to false neutral 
findings in some cases in the past. For example, MAST-E 28 and STIPAS 24 were 
neutral as reported using dichotomous analysis but negative when assessed with 
ordinal approaches.  
 
Several comments can be made about this study. First, it aimed to include data from 
all stroke trials assessing a beneficial or harmful intervention. Unfortunately, data 
were not made available for all identified trials; where possible, we created individual 
data from publications which provided patient numbers by outcome score. Data were 
missing for a variety of trial types (acute/rehabilitation/stroke unit) and sizes, and 
functional outcome measure (mRS/BI), so it is unlikely that a systematic bias was 
introduced into the findings; however, the precision of the results may have been 
attenuated by the missing trials. Second, we did not exhaustively search for all 
possible statistical tests relevant to the problem of analysing ordered categorical data; 
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instead, we focussed on those approaches which are available in standard statistical 
textbooks and computer packages. Additionally, we could not include some tests used 
in recent trials, e.g. patient specific outcomes 29 and Cochran Mantel Haenszel test 30 
since these require access to individual data for both baseline and outcome variables, 
and these data were not available uniformly. Third, some of the statistical 
assumptions underlying the more efficient tests were not met in all trials; for 
example, the t test assumes data are normally distributed while ordinal logistic 
regression assumes that any treatment effect is similar across outcome levels 
(‘proportionality of odds’, i.e. the odds of moving a treated patient from mRS 2 to 1 is 
similar to that for moving them from 5 to 4). Nevertheless, the robustness of these 
tests to deviations from their underlying assumptions means that they remain 
relevant for analysing functional outcome data from stroke trials. 
 
If alternative approaches to analysing functional outcome data are to be used in the 
future, it is pertinent to ask how sample size should be calculated at the trial design 
stage. Historically, most calculations assumed that functional outcome would be 
dichotomised and analysed using a Chi-square test approach.13 Although future trials 
could continue to calculate sample size in the same way (and then gain extra power 
by analysing their data using an ordinal approach), specific sample size calculations 
are available when data are to be analysed using ordinal logistic regression31 or the t-
test. Ideally, the extra power gained by using an ordinal statistical approach should 
not be used to reduce sample size; stroke trials have been too small in the past, as 
shown in a recent meta analysis,13 and this may also have contributed to the failure of 
some of them. 
 
A further issue with using a statistical test which analyses ordered categorical data is 
how to report the results to patients, carers, clinicians, and health policy makers. The 
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results of dichotomous tests may be summarised easily as the proportion of patients 
who benefit (or suffer) with a treatment, i.e. alteplase reduced absolute death or 
dependency (mRS>1) by 13% in the NINDS part 2 trial.1 In contrast, ordinal tests will 
need to be presented as the average absolute improvement in outcome, e.g. alteplase 
improved the mRS by 1 (of 7) point and BI by 22.5 (of 100) points. Alternatively, the 
combined odds ratio and its confidence intervals would be reported if ordinal logistic 
regression was used. In this respect, health consumers will need to decide what 
differences in mRS and BI are worthwhile, both clinically and in terms of health 
economics. In reality, it is reasonable to present the effect on functional outcome 
using both absolute percentage change and mean or median change in functional 
outcome score, and show this data graphically (as in figure 1). 
 
In summary, we suggest that ongoing and future trials should consider using 
statistical approaches which utilise the original ordered categorical data in the primary 
analysis of functional outcome measures. Such ordinal tests include ordinal logistic 
regression, and the robust ranks test; the t-test may also be used although its 
assumptions were not meant in the majority of trials.  
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Table 1. Comparison of rank scores for 16 statistical tests; lower ranks imply the test 
is more efficient. Analysis by two-way ANOVA and Duncan’s multiple comparison 
procedure; tests joined by the same band are not significantly different from each 
other at p<0.05. 
 
 
 
 
Test Mean  
rank 
No. of  
datasets 
Banding 
Ordinal logistic regression 6.11 54       
t-test 6.51 55       
Robust ranks test 6.53 55       
Bootstrap difference in mean rank 6.85 55       
Wilcoxon test 7.31 55       
Cochran-Armitage trend test (4 groups) 7.36 50       
Ordinal logistic regression (4 groups) 7.50 50       
Ordinal logistic regression (3 groups) 7.92 51       
Cochran-Armitage trend test (3 groups) 8.27 51       
Chi Sq – death or poor outcome vs good 8.87 55       
Chi Sq – death or poor outcome vs excellent 9.24 54       
Median test 9.47 55       
Chi Sq – 2x3 test 9.96 51       
Chi Sq – death vs alive 9.98 51       
Chi Sq – 2x4 test 10.02 50       
Kolmogorov-Smirnov test 11.29 55       
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Figure 1 
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OAST Appendix 1: Statistical tests compared 
 
Included tests 
Univariate statistical approaches for analysing dichotomous and ordinal 
data comprised tests based on Chi-square, ordinal, and bootstrap 
approaches.[1-3] Sixteen statistical approaches were assessed: (i) Chi-
square 2x2 test - death or poor outcome vs. good outcome (BI <60 vs. 
60-100, mRS 3-6 vs. 0-2, 3Q 1/2 vs. 3/4); (ii) Chi-square 2x2 test - 
death or poor outcome vs. excellent outcome (BI <95 vs. 95/100, mRS 2-
6 vs. 0/1, 3Q 1-3 vs. 4); (iii) Chi-square 2x2 test - death vs. alive; (iv) 
Chi-square 2x3 test (unordered data) - death vs. poor vs. good outcome; 
(v) Chi-square 2x4 test (unordered data) - death vs. poor outcome vs. 
good outcome vs. excellent outcome; (vi) Cochran-Armitage trend test 
(ordered data with 3 levels) - death vs. poor vs. good outcome); (vii) 
Cochran-Armitage trend test (ordered data with 4 levels) - death vs. poor 
vs. good vs. excellent outcome); (viii) ordinal logistic regression (raw 
data); (ix) ordinal logistic regression (3 levels) (x) ordinal logistic 
regression (4 levels); (xi) median test; (xii) Wilcoxon/Mann-Whitney U 
test (adjusted for ties); (xiii) robust ranks test (RRT [4]); (xiv) 
Kolmogorov-Smirnov test; (xv) t-test (unpooled variances); (xvi) 
bootstrap of difference in mean rank (with 3x3000 cycles [5, 6]). Chi-
square tests were performed without continuity correction since most 
trials enrolled more than 100 patients.  
 
Excluded tests 
Three non-parametric tests were excluded: Wald-Wolfowitz runs test; 
Siegel-Tukey test; and the Cramer-von Mises two-sample test, on 
methodological grounds.[2] 
 
22 
Statistical detail for non-standard tests 
Robust rank test 
The Robust rank test is an alternative to the Wilcoxon test, it tests 
whether the median of one group is equal to another, but unlike the 
Wilcoxon test it does not assume that the distributions of the two groups 
are equal, i.e. it makes no assumptions about the variance of the two 
groups. [3, 4] 
 
Bootstrapping 
Bootstrapping is a computationally intensive method which involves 
resampling data from a given sample. The main advantage of 
bootstrapping over more traditional methods is that it does not make 
assumptions about the distribution of the data. In this report we bootstrap 
the difference in mean rank; the procedure for doing this is outlined 
below: [5] 
1. Take a dataset, which contains N observations 
2. Draw a sample with replacement of size N (using replacement 
means that some of the original observations may appear in the 
new sample more than once and some not at all) 
3. Estimate the parameter of interest (here the difference in mean 
rank) and store the result  
4. Repeat 2 and 3 many times, here we use 3 sets of 3,000 as used in 
the ECASS II trial [6] 
5. Compare the distribution of the stored results to the actual point 
estimate from the original dataset 
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Ordinal logistic regression 
Ordinal logistic regression can be used when the dependent variable is 
ordered categorical. It is similar to logistic regression but it simultaneously 
estimates multiple endpoints instead of just one. The number of endpoints 
it estimates is equivalent to the number of ordered categories minus one. 
For example if the mRS was the dependent variable of interest it would 
compare the following j categories: 
0    vs.    1,2,3,4,5,6 
0,1   vs.    2,3,4,5,6 
0,1,2   vs.    3,4,5,6 
0,1,2,3  vs.    4,5,6 
0,1,2,3,4  vs.    5,6 
0,1,2,3,4,5  vs.    6 
 
Ordinal logistic regression provides one overall estimate for each covariate 
in the model and not one for each cut point. This assumes that the overall 
odds ratio is constant no matter which cut is taken. So, for example the 
odds ratio for the treatment effect would be interpreted as the odds of 
being in category j or above for all choices of j comparing treatment 1 to 
treatment 0. [7] 
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OAST Appendix 2: Supplementary analyses 
 
Supplementary analyses 
 
Sub group analysis 
Sub group analyses were performed by assessing the efficiency of the different tests 
for differing trial characteristics: type of intervention (acute drug treatment, 
rehabilitation, stroke unit); trial size (<500, >500 participants); time between 
randomisation and stroke onset (<6, >6 hours); patient age (median <70, >70 
years); baseline severity (control group death rate adjusted for length of follow up, 
<median (0.05) ,>median); outcome measure (BI, mRS, 3Q); length of follow up (<3 
months, >3 months); and trial result (positive, negative). 
 
Statistical assumptions 
The principal statistical assumptions underlying the tests which performed well were 
assessed to ensure that their use was appropriate for stroke trial data. Assumptions 
included: ordinal logistic regression - proportionality of odds across response 
categories (i.e. the magnitude of improvement or hazard, with a treatment, would be 
similar irrespective of baseline severity, age etc); t-test – normal distribution of 
outcome scores (the use of the unpooled t-test means that homogeneity of variances 
between the treatment groups was not a necessary assumption); robust ranks test – 
independence of treatment groups.[1, 2] 
 
Type 1 error rate 
It is conceivable that an overly sensitive statistical test might find significance in a 
trial when no real difference existed, a type 1 error. We assessed the type I error rate 
for the three most efficient statistical tests, using data from three representative trials 
including one of the three measures of functional outcome (BI: RANTTAS,[3] mRS: 
NINDS,[4] 3Q: IST [5]).  From these we generated 1000 data sets, using random 
sampling with replacement, in which any treatment difference could have occurred 
only by chance. Tests maintaining adherence to the nominal type I error rate would 
expect to see a significant result in around 50 of the 1000 data sets.  
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OAST Appendix 5: Results 
 
Type 1 error rate 
Analysis of 1000 re-sampled random datasets from the 3 trials [1-3] did 
not find any evidence of an increased type I error rate for ordinal logistic 
regression with the number of ‘positive’ data sets being: BI 39/1000 
(p=0.96); mRS 57/1000 (p=0.17) and 3Q 56/1000 (p=0.21). Similar 
results were found for both the t-test and robust ranks test. 
 
Test assumptions 
When assessing ordinal logistic regression, the assumption of 
proportionality of odds (likelihood ratio test comparing the multinomial 
logistic model to the ordinal logistic regression model) was not met 
(p<0.05) in 8 of the 55 data sets (ASK, p=0.001; ASSIST 07, p=0.002; 
ATLANTIS A, p=0.01; citicoline 10, p=0.004; FOOD 3, p=0.04; MAST-I, 
p=0.003; Orpington Domiciliary care, p=0.02; Orpington Team, p=0.02). 
The assumption of normality required for the t-test did not hold for any of 
the data sets. In contrast, the assumption of the robust ranks test was 
met in all cases whilst the bootstrap approach is assumption free. 
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